The Nov Santé Actions Non Cotées Fund, managed by Eurazeo, has finalized its third Growth Equity investment in Germitec, a French MedTech company specializing in high-level disinfection solutions for ultrasound probes. This investment is part of a €29 million Series B fundraising round, with Nov Santé acting as the lead investor alongside existing shareholders, including Kurma Partners, Financière Arbevel, and Turenne Capital.
Germitec, headquartered in Bordeaux, is recognized for its innovative approach to disinfecting ultrasound probes using patented UV-C technology. Their automatic devices, which operate without chemicals, significantly reduce the risk of cross-contamination and offer a user-friendly interface for data management. This environmentally friendly technology provides a viable alternative to traditional chemical disinfection methods, catering to the increasing demands of healthcare professionals.
The global disinfection market is experiencing rapid growth, driven by the need to prevent healthcare-associated infections. In 2023, thousands of deaths in the U.S. and France were attributed to infections acquired in medical settings. Germitec aims to address this critical public health issue by providing tailored solutions for healthcare providers. The company is already present in over 40 countries and is looking to expand into new markets, particularly the United States, where it recently received FDA De Novo certification for its flagship product, Chronos.
This investment by Nov Santé Actions Non Cotées, in collaboration with Kurma Partners, underscores Eurazeo's commitment to strengthening its position in the healthcare sector. The partnership aims to foster innovation and support the emergence of European leaders in healthcare. Germitec is the third Growth Equity investment by Nov Santé, following investments in Kinvent and PanTera.
Vincent Gardès, CEO of Germitec, expressed confidence in the company's growth potential, particularly in the U.S. market, which presents a significant opportunity. He highlighted the importance of Nov Santé and Kurma Partners' expertise in supporting Germitec's development phase.
Arnaud Vincent, Managing Director of Healthcare at Eurazeo, emphasized the firm's pride in being chosen as the lead investor. He noted Germitec's innovative position and the quality of its management as key factors in their decision. Eurazeo's support aims to advance healthcare solutions that tackle major public health challenges, particularly in preventing nosocomial infections, while also promoting French healthcare sovereignty through domestically produced products.
